News about Clinical Trials

Takeda's Oveporexton Improves Daily Function in Narcolepsy Type 1

Takeda’s phase 3 data show oveporexton improved daily function, cognition, and nighttime sleep in people with narcolepsy type 1. The results support the potential of the first orexin agonist therapy, with regulatory submissions currently under review.

Clinical Trials | 16/06/2026 | By News Bureau

Suven Life Sciences Reports Positive Phase 1 Results for SUVN-I6107

Suven Life Sciences has reported positive topline results from the First-in-Human phase 1 study of SUVN-I6107, a Muscarinic M1 Positive Allosteric Modulator (M1-PAM). The successful trial supports the advancement of SUVN-I6107 into phase 2 clinical development.

Clinical Trials | 16/06/2026 | By News Bureau

Celldex Reports Sustained Angioedema Improvement with Barzolvolimab in CSU

Celldex presented long-term data showing barzolvolimab delivered sustained off-treatment improvement in angioedema among patients with Chronic Spontaneous Urticaria (CSU).Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU.

Clinical Trials | 16/06/2026 | By News Bureau

Lilly's Jaypirca Cuts Disease Progression Risk by 45 Percent in CLL/SLL

Lilly’s Jaypirca (pirtobrutinib) reduced the risk of disease progression or death by 45 percent when combined with a time-limited venetoclax regimen in previously treated CLL/SLL patients, according to phase 3 BRUIN CLL-322 trial results.

Clinical Trials | 15/06/2026 | By News Bureau

Suven Life Sciences Announces 3 Poster Presentations on Samelisant

Suven Life Sciences showcases 3 posters on Samelisant (SUVN-G3031), including findings from the global phase 3 AWAKE Narcolepsy Study at SLEEP 2026.

Clinical Trials | 12/06/2026 | By News Bureau

Del-Brax from Novartis Achieves Primary Biomarker Endpoint in FSHD Study

Novartis reported positive phase 1/2 FORTITUDE study results for delpacibart braxlosiran (del-brax) in FSHD, meeting primary and key secondary biomarker endpoints. The therapy could become the first disease-modifying treatment for FSHD, with a phase 3 trial underway.

Clinical Trials | 12/06/2026 | By News Bureau

Lilly's Oral GLP-1 Foundayo Shows Superior A1C Control and Weight Loss in Type 2 Diabetes

Lilly’s oral GLP-1 drug Foundayo (orforglipron) delivered superior A1C control and weight loss in 3 pivotal Type 2 Diabetes (T2D) trials, outperforming oral semaglutide and helping more patients achieve glycemic targets.

Clinical Trials | 10/06/2026 | By News Bureau

Life Biosciences Doses First Patient in Phase 1 ER-100 Optic Neuropathy Trial

Life Biosciences has dosed the first patient in its phase 1 trial of ER-100, an investigational epigenetic restoration therapy for glaucoma and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION). The study marks a key milestone in evaluating a novel approach that targets the underlying causes of age-related vision loss.

Clinical Trials | 09/06/2026 | By News Bureau |  357

Gilead and Merck Report Positive Phase 3 Results for Weekly HIV Pill

Gilead and Merck reported positive phase 3 results for the investigational once-weekly oral HIV therapy islatravir/lenacapavir, which has the potential to become the first approved long-acting weekly oral treatment for people living with HIV.

Clinical Trials | 09/06/2026 | By News Bureau

Coya Therapeutics Advances ALSTARS Trial into Active-Treatment Extension Phase

Coya Therapeutics announced that the first cohort of ALS patients in the ALSTARS trial has entered the 24-week blinded active-treatment extension phase, where all participants will receive COYA 302.

Clinical Trials | 09/06/2026 | By News Bureau